<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002647</url>
  </required_header>
  <id_info>
    <org_study_id>14-2021/13</org_study_id>
    <nct_id>NCT05002647</nct_id>
  </id_info>
  <brief_title>Relationship Between the Clinical Pharmacist &amp; Antibiotic Use by Using the Electronic Program</brief_title>
  <official_title>Relationship Between the Clinical Pharmacist &amp; Antibiotic Use in Selected Infectious Disease Hospitals in El Beheira by Using the Electronic Program, Retrospective Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health and Population, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A retrospective cohort study to explore the association between clinical pharmacists'&#xD;
      interventions and antibiotic consumption through the use of the medical electronic reports&#xD;
      and to identify mortality and cost savings in hospital infectious disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of clinical pharmacist includes :&#xD;
&#xD;
        1. a check of suitable selection and dosing of antimicrobials according to the diagnosis,&#xD;
           type of infection, antimicrobial cultures as possible, comorbidities of patients (renal&#xD;
           or hepatic function, etc), adverse effect, and drug interaction with other drugs.&#xD;
&#xD;
        2. Documentation of the clinical intervention, cost-saving, adverse effect,, antimicrobial&#xD;
           culture and antimicrobial consumption on the electronic program (CPC &quot;clinical patient&#xD;
           care&quot;).&#xD;
&#xD;
        3. The clinical pharmacist inspector reviews the data recorded on CPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial consumption</measure>
    <time_frame>2 years</time_frame>
    <description>consumption of antimicrobials (defined daily doses / 100 patient-days)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Days of therapy (DOT)</measure>
    <time_frame>2 years</time_frame>
    <description>Number of days of each antimicrobial received for therapy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of therapy(LOT)</measure>
    <time_frame>2 years</time_frame>
    <description>The number of days a patient takes an antibacterial drug, regardless of the number of different medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost savings</measure>
    <time_frame>2 years</time_frame>
    <description>(initial treatment cost × days before intervention) - (cost after intervention × days with this treatment),</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>2 years</time_frame>
    <description>in-hospital mortality rate (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antimicrobial resistance</measure>
    <time_frame>2 years</time_frame>
    <description>resistance defined as resistance to at least one antimicrobial from the panel for all organisms, and for a subset of organisms belonging to the ESKAPE group (Enterococcus faecium, S. aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa , and Enterobacter spp.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse reaction of antimicrobial</measure>
    <time_frame>2 years</time_frame>
    <description>An unexpected medical problem that happens during treatment with antimicrobial.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Clinical Pharmacists</condition>
  <condition>Electronic Medical Record</condition>
  <arm_group>
    <arm_group_label>exposure group</arm_group_label>
    <description>Data from electronic clinical pharmacist records of two infectious disease hospitals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposure group A</arm_group_label>
    <description>Data from medical records of the hospital with no clinical pharmacy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-exposure group B</arm_group_label>
    <description>Data from a medical record of the hospital with clinical pharmacy, but the department did not cover by the clinical pharmacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NO intervention</intervention_name>
    <description>There is no intervention</description>
    <arm_group_label>Non-exposure group A</arm_group_label>
    <arm_group_label>Non-exposure group B</arm_group_label>
    <arm_group_label>exposure group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who administered antimicrobials&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All inpatient with infectious disease (disorders caused by organisms as (bacteria,&#xD;
             viruses, fungi, or parasites).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any other cause of hospital admission other than infectious disease.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amira zidane</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health and Population, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amira zidane</last_name>
    <phone>00201024585329</phone>
    <email>amira.zidan2yahoo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maged El-Setouhy</last_name>
    <email>ma.elsetouhy@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Karakonstantis S, Kalemaki D. Antimicrobial overuse and misuse in the community in Greece and link to antimicrobial resistance using methicillin-resistant S. aureus as an example. J Infect Public Health. 2019 Jul - Aug;12(4):460-464. doi: 10.1016/j.jiph.2019.03.017. Epub 2019 Apr 10. Review.</citation>
    <PMID>30981652</PMID>
  </reference>
  <reference>
    <citation>Dyar OJ, Huttner B, Schouten J, Pulcini C; ESGAP (ESCMID Study Group for Antimicrobial stewardshiP). What is antimicrobial stewardship? Clin Microbiol Infect. 2017 Nov;23(11):793-798. doi: 10.1016/j.cmi.2017.08.026. Epub 2017 Sep 4. Review.</citation>
    <PMID>28882725</PMID>
  </reference>
  <reference>
    <citation>Ourghanlian C, Lapidus N, Antignac M, Fernandez C, Dumartin C, Hindlet P. Pharmacists' role in antimicrobial stewardship and relationship with antibiotic consumption in hospitals: An observational multicentre study. J Glob Antimicrob Resist. 2020 Mar;20:131-134. doi: 10.1016/j.jgar.2019.07.009. Epub 2019 Jul 16.</citation>
    <PMID>31323427</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 7, 2021</study_first_submitted>
  <study_first_submitted_qc>August 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 13, 2021</last_update_submitted>
  <last_update_submitted_qc>August 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical pharmacist</keyword>
  <keyword>antibiotic consumption</keyword>
  <keyword>antibiotic use</keyword>
  <keyword>cost-saving</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

